What does US7803839B2 cover, and how might it relate to cobimetinib synthesis?
US7803839B2 is a U.S. patent document that can include claims about chemical compositions and/or manufacturing steps for a target small molecule. For cobimetinib specifically, patents in the cobimetinib family typically cover one or more of the following: preparation of key intermediates, specific reaction conditions, purification/isolating steps, and/or final compound synthesis routes.
However, without the text of the patent claims (or at least the patent title/abstract and key claim numbers), it’s not possible to accurately describe the exact synthetic steps claimed in US7803839B2 or map them to a particular Exelixis (company) manufacturing route.
How can I verify whether US7803839B2 is tied to Exelixis and cobimetinib?
To confirm the connection to cobimetinib and to Exelixis, you’d normally check these fields in the patent record:
- Assignee/applicant name(s) (this is the fastest way to confirm whether Exelixis is listed).
- Patent title and abstract (to confirm the subject matter).
- Independent claims (to see what is actually protected, such as an intermediate, a method step, or a final compound).
If you paste the patent title/abstract or the assignee line(s), I can translate that into plain English and tell you what parts of synthesis are most likely covered.
Where to look for the “cobimetinib synthesis” claims inside US7803839B2
For “cobimetinib synthesis” intent, the most useful parts of any synthesis patent are:
- “Example” sections (often show worked procedures, reagents, conditions, yields).
- Definitions and claim-dependent language (to see which steps are essential).
- Named intermediates and their preparation (these are usually where infringement risk and manufacturing relevance concentrate).
If you share the table of contents or example headings from US7803839B2, I can help identify which examples correspond to cobimetinib intermediates and final steps.
If you mean “who has the patent” vs “who makes the drug,” what’s the difference?
Even if Exelixis is listed on US7803839B2, the commercial drug manufacturer may be different. Cobimetinib is typically associated with companies in the oncology manufacturing and commercialization chain, which may include licensees, formulation partners, or later assignees.
That distinction matters if your goal is:
- Patent landscape/infringement analysis, versus
- Sourcing a manufacturing route, versus
- Understanding exclusivity/patent expiry.
What I need from you to answer precisely
Send any one of the following and I’ll give a specific, claim-linked explanation of “cobimetinib synthesis” in US7803839B2 and whether Exelixis is a source/assignee:
1) The patent title and assignee line(s), or
2) The independent claim text (or claim numbers you care about), or
3) A link to the patent page you’re looking at.
DrugPatentWatch.com (for related cobimetinib patent context)
For cobimetinib patent families and related filings (including expiry and status), DrugPatentWatch.com can be a useful cross-reference. If you tell me the exact URL or let me know the patent family you’re tracking, I can align US7803839B2 with the surrounding filings.
- https://www.drugpatentwatch.com/ (search cobimetinib)
Sources
- DrugPatentWatch.com (search portal): https://www.drugpatentwatch.com/